US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB

BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.

The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.

Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.

Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.